Allianz Asset Management GmbH Has $29.74 Million Stake in Insulet Co. (NASDAQ:PODD)

Allianz Asset Management GmbH boosted its position in shares of Insulet Co. (NASDAQ:PODD) by 27.7% during the 4th quarter, HoldingsChannel.com reports. The fund owned 113,921 shares of the medical instruments supplier’s stock after buying an additional 24,734 shares during the quarter. Allianz Asset Management GmbH’s holdings in Insulet were worth $29,741,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PODD. Baillie Gifford & Co. lifted its stake in Insulet by 20.7% in the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after purchasing an additional 389,639 shares during the last quarter. Mizuho Securities USA LLC lifted its position in shares of Insulet by 5,928.1% in the third quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock valued at $75,835,000 after buying an additional 320,416 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Insulet by 43.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after acquiring an additional 193,839 shares during the period. Westfield Capital Management Co. LP increased its holdings in shares of Insulet by 27.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after acquiring an additional 163,388 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec bought a new stake in Insulet in the 3rd quarter valued at $16,342,000.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Canaccord Genuity Group upped their price target on shares of Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday. TD Cowen upped their target price on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Morgan Stanley increased their target price on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Barclays boosted their price target on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Finally, JPMorgan Chase & Co. increased their price objective on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research report on Thursday, December 12th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, Insulet has an average rating of “Moderate Buy” and a consensus target price of $289.06.

Insulet Trading Down 1.9 %

PODD opened at $282.80 on Monday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $289.46. The stock has a market capitalization of $19.84 billion, a price-to-earnings ratio of 48.84, a P/E/G ratio of 3.62 and a beta of 1.23. The company has a 50-day simple moving average of $272.98 and a 200 day simple moving average of $247.87.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Analysts predict that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling at Insulet

In related news, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.